| __timestamp | Alnylam Pharmaceuticals, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 246000000 |
| Thursday, January 1, 2015 | 276495000 | 582800000 |
| Friday, January 1, 2016 | 382392000 | 455000000 |
| Sunday, January 1, 2017 | 390635000 | 366000000 |
| Monday, January 1, 2018 | 505420000 | 414000000 |
| Tuesday, January 1, 2019 | 655114000 | 471000000 |
| Wednesday, January 1, 2020 | 654819000 | 452000000 |
| Friday, January 1, 2021 | 792156000 | 465000000 |
| Saturday, January 1, 2022 | 883015000 | 529000000 |
| Sunday, January 1, 2023 | 1004415000 | 604000000 |
| Monday, January 1, 2024 | 1126232000 |
Cracking the code
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals and Bausch Health Companies have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Alnylam Pharmaceuticals has shown a remarkable 428% increase in R&D expenses, reflecting its dedication to pioneering RNA interference therapeutics. By 2023, Alnylam's R&D spending reached its peak, underscoring its strategic focus on cutting-edge research.
In contrast, Bausch Health Companies maintained a more stable R&D expenditure, with a 146% increase over the same period. This steady investment highlights Bausch's commitment to enhancing its existing product lines while exploring new therapeutic avenues.
These trends reveal the diverse strategies of two industry leaders, each navigating the complex world of pharmaceutical innovation in their unique way.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Bausch Health Companies Inc.